摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(1-苄基-1H-咪唑-5-基)乙酮 | 189353-88-6

中文名称
1-(1-苄基-1H-咪唑-5-基)乙酮
中文别名
——
英文名称
1-(3-benzyl-3H-imidazol-4-yl)ethanone
英文别名
5-Acetyl-1-benzylimidazole;1-(1-benzyl-1H-imidazol-5-yl)ethanone;1-(3-benzylimidazol-4-yl)ethanone
1-(1-苄基-1H-咪唑-5-基)乙酮化学式
CAS
189353-88-6
化学式
C12H12N2O
mdl
——
分子量
200.24
InChiKey
BLQNOZHGIDFFAS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    34.9
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    1-(1-苄基-1H-咪唑-5-基)乙酮盐酸肼lithium hexamethyldisilazane 作用下, 以 乙醚乙醇 为溶剂, 反应 2.0h, 生成 Ethyl 3-(1-benzyl-1H-imidazol-4-yl)-1H-pyrazole-5-carboxylate
    参考文献:
    名称:
    [EN] ANDROGEN RECEPTOR MODULATING CARBOXAMIDES
    [FR] CARBOXAMIDES MODULANT LES RÉCEPTEURS D'ANDROGÈNES
    摘要:
    公式(I)中的化合物,其中Rx、Rz、R9、R10、R14、R14'、R15、R15'、A和B的定义如索赔中所述,并且其药学上可接受的盐和酯已被披露。这些化合物具有作为组织选择性雄激素受体调节剂(SARM)的效用,并且在治疗前列腺癌和其他依赖于雄激素受体的疾病和病症中特别有用,其中需要AR拮抗作用。
    公开号:
    WO2012143599A1
  • 作为产物:
    描述:
    溴甲苯4-乙酰基咪唑sodium hydroxide四丁基溴化铵 作用下, 以 甲苯 为溶剂, 反应 4.0h, 生成 1-(1-苄基-1H-咪唑-5-基)乙酮 、 4-acetyl-1-benzylimidazole
    参考文献:
    名称:
    Regioselective Alkylation of 2-Alkyl-5,6,7,8-tetrahydro-3H-cycloheptimidazol-4-ones and 2-Alkyl-3H-cycloheptimidazol-4-ones
    摘要:
    研究了2-烷基-5,6,7,8-四氢-3H-环庚咪唑-4-酮(1)和2-烷基-3H-环庚咪唑-4-酮(2)的区域选择性烷基化反应。在DMF或THF中使用NaH的条件下,优先得到3-[2′-(1-叔丁基-1H-四唑-5-基)联苯-4-基甲基]-2-丙基-5,6,7,8-四氢-1H-环庚咪唑-4-酮(6)。另一方面,在甲苯中使用水合氢氧化钠作为碱和n-Bu4NBr存在下,选择性得到3-[2′-(1-叔丁基-1H-四唑-5-基)联苯-4-基甲基]-2-丙基-5,6,7,8-四氢-3H-环庚咪唑-4-酮(5),即普拉托沙坦的合成中间体化合物。在这项反应中,发现碱性溶液的浓度影响其区域选择性。这种选择性甚至在醛和酯衍生物中也观察到。
    DOI:
    10.1248/cpb.54.706
点击查看最新优质反应信息

文献信息

  • [EN] ANDROGEN RECEPTOR MODULATING CARBOXAMIDES<br/>[FR] CARBOXAMIDES MODULANT LES RÉCEPTEURS D'ANDROGÈNES
    申请人:ORION CORP
    公开号:WO2012143599A1
    公开(公告)日:2012-10-26
    Compounds of formula (I) wherein Rx, Rz, R9, R10, R14, R14', R15, R15', A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.
    公式(I)中的化合物,其中Rx、Rz、R9、R10、R14、R14'、R15、R15'、A和B的定义如索赔中所述,并且其药学上可接受的盐和酯已被披露。这些化合物具有作为组织选择性雄激素受体调节剂(SARM)的效用,并且在治疗前列腺癌和其他依赖于雄激素受体的疾病和病症中特别有用,其中需要AR拮抗作用。
  • Imidazole derivatives having affinity for alpha2 receptors
    申请人:Orion Corporation
    公开号:US06313311B1
    公开(公告)日:2001-11-06
    Imidazole derivatives of formula (I) wherein n is 0 or 1, R1 is hydrogen or C1-C4-alkyl, R2 is hydrogen or R2 and R3 together form a double bond, R3 is hydrogen or C1-C4-alkyl or R2 and R3 together form a double bond, R4 is hydrogen, C1-C4-alkyl, hydroxy or C1-C4-alkoxy, R5 is hydrogen or C1-C4-alkyl or R4 and R5 together with the carbon atom to which they are attached form a carbonyl group, R6, R7 and R8 are each the same or different and are independently hydrogen, C1-C4-alkyl or C2-C4-alkenyl, C3-C7-cycloalkyl, hydroxy, C1-C4-alkoxy, C1-C4-hydroxyalkyl, thiol, C1-4-alkylthio, C1-4-alkylthiol, halogen, trifluoromethyl, nitro or optionally substituted amino, X is —CHR9—(CHR10)m—, m is 0 or 1, and R9 and R10 are each the same or different and are independently hydrogen or C1-C4-alkyl; or a pharmaceutically acceptable ester or salt thereof, their preparation, use and pharmaceutical compositions comprising them are described. The compounds have affinity for alpha2 receptors and are useful e.g. in the treatment of hypertension, glaucoma, chronic or acute pain, migraine, diarrhea, common cold, ischemia, addiction to chemical substances, anxiety, especially preoperative anxiety and different neurological, musculoskeletal, psychiatric and cognition disorders or as adjuncts to anesthesia.
    Imidazole衍生物的化学式(I),其中n为0或1,R1为氢或C1-C4-烷基,R2为氢或R2和R3共同形成双键,R3为氢或C1-C4-烷基或R2和R3共同形成双键,R4为氢,C1-C4-烷基,羟基或C1-C4-烷氧基,R5为氢或C1-C4-烷基或R4和R5与它们连接的碳原子共同形成羰基,R6、R7和R8分别相同或不同且独立地为氢、C1-C4-烷基或C2-C4-烯基、C3-C7-环烷基、羟基、C1-C4-烷氧基、C1-C4-羟基烷基、硫醇、C1-4-烷基硫醚、C1-4-烷基硫醇、卤素、三氟甲基、硝基或可选择取代的氨基,X为—CHR9—(CHR10)m—,m为0或1,R9和R10分别相同或不同且独立地为氢或C1-C4-烷基;或者其药学上可接受的酯或盐,描述了它们的制备、用途和包括它们的药物组合物。这些化合物对α2受体具有亲和力,可用于治疗高血压、青光眼、慢性或急性疼痛、偏头痛、腹泻、普通感冒、缺血、对化学物质的成瘾、焦虑,特别是围手术期焦虑以及不同的神经、肌肉骨骼、精神和认知障碍或作为麻醉的辅助剂。
  • [EN] IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY<br/>[FR] DERIVES D'IMIDAZOLE A AFFINITE POUR L'ACTIVITE DE RECEPTEURS ALPHA2
    申请人:ORION-YHTYMÄ OY
    公开号:WO1997012874A1
    公开(公告)日:1997-04-10
    (EN) Imidazole derivatives of formula (I), wherein n is 0 or 1, R1 is hydrogen or C1-C4-alkyl, R2 is hydrogen or R2 and R3 together form a double bond, R3 is hydrogen or C1-C4-alkyl or R2 and R3 together form a double bond, R4 is hydrogen, C1-C4-alkyl, hydroxy or C1-C4-alkoxy, R5 is hydrogen or C1-C4-alkyl or R4 and R5 together with the carbon atom to which they are attached form a carbonyl group, R6, R7 and R8 are each the same or different and are independently hydrogen, C1-C4-alkyl or C2-C4-alkenyl, C3-C7-cycloalkyl, hydroxy, C1-C4-alkoxy, C1-C4-hydroxyalkyl, thiol, C1-4-alkylthio, C1-4-alkylthiol, halogen, trifluoromethyl, nitro or optionally substituted amino, X is -CHR9-(CHR10)m-, m is 0 or 1, and R9 and R10 are each the same or different and are independently hydrogen or C1-C4-alkyl; or a pharmaceutically acceptable ester or salt thereof, their preparation, use and pharmaceutical compositions comprising them are described. The compounds have affinity for alpha2 receptors and are useful e.g. in the treatment of hypertension, glaucoma, chronic or acute pain, migraine, diarrhea, common cold, ischemia, addiction to chemical substances, anxiety, especially preoperative anxiety and different neurological, musculoskeletal, psychiatric and cognition disorders or as adjuncts to anesthesia.(FR) L'invention porte sur des dérivés d'imidazole de la formule (I) dans laquelle n vaut 0 ou 1, R1 représente un hydrogène ou un alkyle C1-C4, R2 représente un hydrogène ou bien R2 et R3 forment ensemble une double liaison, R3 représente un hydrogène ou un alkyle C1-C4 ou R2 et R3 forment ensemble une double liaison, R4 représente un hydrogène ou un alkyle C1-C4, un hydroxy ou un alcoxy C1-C4, R5 représente un hydrogène ou un alkyle C1-C4 ou bien R4 et R5, avec l'atome de carbone auquel ils sont rattachés, forment un groupe carbonyle, R6, R7 et R8 sont chacun identiques ou différents et représentent indépendamment un hydrogène, un alkyle C1-C4 ou un alcényle C2-C4, un cycloalkyle C3-C7, un hydroxy, un alcoxy C1-C4, un hydroxyalkyle C1-C4, un thiol, un alkylthio C1-C4, un alkylthiol C1-C4, un halogène, un trifluorométhyle, un nitro ou un amino éventuellement substitué, formule dans laquelle X représente -CHR9-(CHR10)m-, m valant 0 ou 1 et R9 et R10 étant chacun identiques ou différents et représentant indépendamment un hydrogène ou un alkyle C1-C4. L'invention porte également sur un ester ou un sel de ces dérivés, acceptables du point de vue pharmaceutique, sur leur préparation, leur utilisation, ainsi que sur des compositions pharmaceutiques les comportant. Ces composés, qui ont une affinité pour des récepteurs alpha2, s'avèrent efficaces dans le traitement de l'hypertension, du glaucome, de douleurs chroniques ou aiguës, de la migraine, de la diarrhée, du rhume banal, de l'ischémie, de l'accoutumance à des substances chimiques, de l'anxiété, notamment de l'angoisse préopératoire et de différents troubles neurologiques, de troubles des muscles du squelette, de troubles psychiatriques et cognitifs de même qu'ils peuvent constituer des produits d'appoint pour les anesthésies.
    (I)式的咪唑衍生物,其中n为0或1,R1为氢或C1-C4-烷基,R2为氢或R2和R3共同形成双键,R3为氢或C1-C4-烷基或R2和R3共同形成双键,R4为氢,C1-C4-烷基,羟基或C1-C4-烷氧基,R5为氢或C1-C4-烷基或R4和R5与它们所连接的碳原子形成羰基,R6、R7和R8各自相同或不同且独立地为氢、C1-C4-烷基或C2-C4-烯基、C3-C7-环烷基、羟基、C1-C4-烷氧基、C1-C4-羟基烷基、硫醇、C1-4-烷基硫醚、C1-4-烷基硫醇、卤素、三氟甲基、硝基或可选择取代的氨基,X为-CHR9-(CHR10)m-,m为0或1,R9和R10各自相同或不同且独立地为氢或C1-C4-烷基;或其药学上可接受的酯或盐,其制备、用途和包含它们的制药组合物也被描述。这些化合物具有对α2受体的亲和力,可用于治疗高血压、青光眼、慢性或急性疼痛、偏头痛、腹泻、普通感冒、缺血、对化学物质的成瘾、焦虑,特别是术前焦虑以及不同的神经、肌肉骨骼、精神和认知障碍或作为麻醉的辅助剂。
  • Selective aromatase inhibiting 4(5)-imidazoles
    申请人:Orion-yhtyma Oy
    公开号:US05559141A1
    公开(公告)日:1996-09-24
    New 4(5)-imidazole derivatives of formula (Ia) and (Ib) wherein one of R.sub.1 and R.sub.2 is CN and the other one is H, CH.sub.3, OCH.sub.3, NO.sub.2, NH.sub.2, CN, CF.sub.3, CHF.sub.2, CH.sub.2 F or halogen; R' is H or (II) where R.sub.3 is H, CH.sub.3 or halogen; R.sub.4 is H and R.sub.5 is H or R.sub.4 and R.sub.5 together form a bond, n is 1 or 2 and y is 0 to 2, their stereoisomers and their non-toxic pharmaceutically acceptable acid addition salts exhibit selective aromatase inhibiting properties, compared with their desmolase inhibiting properties. The compounds of the invention are valuable in the treatment of estrogen dependent diseases, e.g. breast cancer or benign prostatic hyperplasia (BPH).
    公式(Ia)和(Ib)的新4(5)-咪唑衍生物,其中R.sub.1和R.sub.2中的一个是CN,另一个是H,CH.sub.3,OCH.sub.3,NO.sub.2,NH.sub.2,CN,CF.sub.3,CHF.sub.2,CH.sub.2 F或卤素;R'为H或(II),其中R.sub.3为H,CH.sub.3或卤素;R.sub.4为H,R.sub.5为H或R.sub.4和R.sub.5一起形成键,n为1或2,y为0到2,它们的立体异构体和其非毒性制药可接受酸盐表现出比它们的去甲烷激素抑制作用更具选择性的芳香化酶抑制作用。该发明的化合物在治疗雌激素依赖性疾病,例如乳腺癌或良性前列腺增生症(BPH)方面非常有价值。
  • Imidazole derivatives having affinity for &agr;2 receptors
    申请人:Orion Corporation
    公开号:US06479530B2
    公开(公告)日:2002-11-12
    Imidazole derivatives of formula I wherein n is 0 or 1, R1 is hydrogen or C1-C4-alkyl, R2 is hydrogen or R2 and R3 together form a double bond, R3 is hydrogen or C1-C4-alkyl or R2 and R3 together form a double bond, R4 is hydrogen, C1-C4-alkyl, hydroxy or C1-C4-alkoxy, R5 is hydrogen or C1-C4-alkyl or R4 and R5 together with the carbon atom to which they are attached form a carbonyl group, R6, R7 and R8 are each the same or different and are independently hydrogen, C1-C4-alkyl or C2-C4-alkenyl, C3-C7-cycloalkyl, hydroxy, C1-C4-alkoxy, C1-C4-hydroxyalkyl, thiol, C1-4-alkylthio, C1-4-alkylthiol, halogen, trifluoromethyl, nitro or optionally substituted amino, X is —CHR9—(CHR10)m—, m is 0 or 1, and R9 and R10 are each the same or different and are independently hydrogen or C1-C4-alkyl; or a pharmaceutically acceptable ester or salt thereof, their preparation, use and pharmaceutical compositions comprising them are described. The compounds have affinity for alpha2 receptors and are useful e.g. in the treatment of hypertension, glaucoma, chronic or acute pain, migraine, diarrhea, common cold, ischemia, addiction to chemical substances, anxiety, especially preoperative anxiety and different neurological, musculoskeletal, psychiatric and cognition disorders or as adjuncts to anesthesia.
    公式I的咪唑衍生物,其中n为0或1,R1为氢或C1-C4-烷基,R2为氢或R2和R3一起形成双键,R3为氢或C1-C4-烷基或R2和R3一起形成双键,R4为氢,C1-C4-烷基,羟基或C1-C4-烷氧基,R5为氢或C1-C4-烷基或R4和R5与它们所连接的碳原子一起形成羰基,R6,R7和R8各自相同或不同且独立地为氢,C1-C4-烷基或C2-C4-烯基,C3-C7-环烷基,羟基,C1-C4-烷氧基,C1-C4-羟基烷基,硫醇,C1-4-烷基硫醚,C1-4-烷基硫醇,卤素,三氟甲基,硝基或可选取代的氨基,X为-CHR9-(CHR10)m-,m为0或1,R9和R10各自相同或不同且独立地为氢或C1-C4-烷基;或其药学上可接受的酯或盐,其制备、用途和包含它们的制药组合物被描述。这些化合物具有对α2受体的亲和力,可用于治疗高血压、青光眼、慢性或急性疼痛、偏头痛、腹泻、普通感冒、缺血、对化学物质的成瘾、焦虑,特别是术前焦虑以及不同的神经、肌肉骨骼、精神和认知障碍或作为麻醉剂的辅助剂。
查看更多